The North America Preimplantation Genetics Diagnosis (PGD) Market would witness Market growth of 8.5% CAGR during the forecast period (2022-2028).
PGD is widely used in in-vitro fertilization genetic testing to detect genetic problems in embryos. PGD has been shown to reduce the likelihood of generating unhealthy embryos. Furthermore, it considerably improves the odds of a healthy pregnancy. In addition, the rise in infertility rates, as well as genetic, hereditary, and chromosomal problems, boosted Market expansion. Furthermore, technological improvements in PGD give benefits, such as the capacity to prevent impairment in kids and the generation of unhealthy savior siblings when PGD is combined with HLA. Furthermore, PGD showed a positive response in patients with recurrent IVF failures, low sperm count, and advanced maternal age who were trying to conceive.
In addition, it improves the odds of having a healthy pregnancy. In addition, factors such as increasing intake of alcohol, drugs, smoking, and poor food; increased stress; greater exposure to environmental contaminants; and an increase in health problems linked to hormones have all contributed to an increase in infertility cases around the world. This has increased the usage of IVF, which has had a beneficial impact on the growth of the Market . Moreover, benefits such as the development of savior siblings and the increased adoption of assisted reproductive technology (ART) in underdeveloped nations are projected to boost the PGD industry. Furthermore, an increase in the risk of fatal genetic, hereditary, and chromosomal illnesses such as Duchenne muscular dystrophy, Down syndrome, cystic fibrosis, triploidy, and thalassemia encourages patients to choose PGD, thereby boosting the growth of the Market .
Abnormalities, which can lead to a variety of genetic illnesses. Aneuploidy is the most common cause of Down syndrome in newborn babies in the United States, which accounts for the majority of the North American Market 's income. According to a report issued by the World Health Organization in 2018, down syndrome remains the most common chromosomal abnormality, impacting 6,000 newborns born in the United States each year.
As a result, there is a strong demand for earlier detection to detect genetic problems in embryos. More income is generated by important players launching new products and a surge in improvements in healthcare infrastructure in the United States. One of the key trends in the regional Market is an increase in government activities to raise public awareness and a growing preference among couples for these tests during IVF and other artificial insemination procedures.
The US Market dominated the North America Preimplantation Genetics Diagnosis (PGD) Market by Country in 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $41.8 million by 2028. The Canada Market is experiencing a CAGR of 11% during (2022 - 2028). Additionally, The Mexico Market would showcase a CAGR of 10% during (2022 - 2028).
Based on Test Type, the Market is segmented into Aneuploidy, Chromosomal Abnormalities, X-linked diseases, Single Gene Disorders, HLA Typing, Gender selection, and Others. Based on countries, the Market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Preimplantation Genetics Diagnosis (PGD) Market is Estimated to reach $159.8 Million by 2028, at a CAGR of 9.7%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Illumina, Inc., Invitae Corporation, Natera, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, PacGenomics, CeGaT GmbH, and Laboratory Corporation of America Holdings.
By Test Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
